{"id":2652,"date":"2021-05-05T11:44:49","date_gmt":"2021-05-05T11:44:49","guid":{"rendered":"http:\/\/www.cscr.in\/nahd\/?p=2652"},"modified":"2021-05-10T10:41:22","modified_gmt":"2021-05-10T10:41:22","slug":"lentiviral-gene-therapy-approach-for-haemoglobinopathies","status":"publish","type":"post","link":"https:\/\/www.cscr.res.in\/nahd\/lentiviral-gene-therapy-approach-for-haemoglobinopathies\/","title":{"rendered":"Lentiviral Gene Therapy Approach for Haemoglobinopathies"},"content":{"rendered":"<div id=\"pl-2652\"  class=\"panel-layout\" ><div id=\"pg-2652-0\"  class=\"panel-grid panel-has-style\" ><div class=\"panel-row-style panel-row-style-for-2652-0\" ><div id=\"pgc-2652-0-0\"  class=\"panel-grid-cell\" ><div id=\"panel-2652-0-0-0\" class=\"widget_text so-panel widget widget_custom_html panel-first-child\" data-index=\"0\" ><div class=\"textwidget custom-html-widget\"><div class=\"sp-title-cscr-post title-mbottom text-left\">\n<h3>Lentiviral Gene Therapy Approach for Haemoglobinopathies<\/h3>\n<\/div>\n<ul class=\"list-post-sp\">\t\n\t<li>Novel beta and gamma globin gene addition vectors have been generated and evaluated by exvivo erythropoiesis models and mouse models for its therapeutical application in sickle cell disease and beta-thalassaemia<\/li>\n<li>In another strategy, an efficient lentiviral vector for the erythroid cell specific expression of BCL11A shRNA has been generated. This vector has been evaluated by the ex-vivo erythropoiesis of transduced CD34+ cells and by transplantation of these cells in NSG and NBSGW mice for testing the potential of the vector to increase foetal haemoglobin (HbF).<\/li>\n<\/ul><\/div><\/div><div id=\"panel-2652-0-0-1\" class=\"widget_text so-panel widget widget_custom_html\" data-index=\"1\" ><div class=\"textwidget custom-html-widget\"><div class=\"sp-co-sub\">\n<p>\n<span class=\"color-red\">Principal Investigator:<\/span><br>\n\t<a class=\"ref-color-anchor-black\" href=\"http:\/\/www.cscr.res.in\/dr-shaji-r-velayudhan\/\" target=\"_blank\" rel=\"noopener\"><span class=\"color-bold-1\">Dr. Shaji R.V.,<\/span> <span class=\"inves-dept\">Department of Haematology, CMC and CSCR, Vellore<\/span><\/a>\n<\/p>  \t\n<\/div><\/div><\/div><div id=\"panel-2652-0-0-2\" class=\"so-panel widget widget_media_image panel-last-child\" data-index=\"2\" ><img width=\"410\" height=\"230\" src=\"https:\/\/www.cscr.res.in\/nahd\/jb-content\/uploads\/2021\/03\/lentrival-post2.jpg\" class=\"image wp-image-1802  attachment-full size-full\" alt=\"lentrival-post\" loading=\"lazy\" style=\"max-width: 100%; height: auto;\" srcset=\"https:\/\/www.cscr.res.in\/nahd\/jb-content\/uploads\/2021\/03\/lentrival-post2.jpg 410w, https:\/\/www.cscr.res.in\/nahd\/jb-content\/uploads\/2021\/03\/lentrival-post2-300x168.jpg 300w\" sizes=\"(max-width: 410px) 100vw, 410px\" \/><\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Lentiviral Gene Therapy Approach for Haemoglobinopathies Novel beta and gamma globin gene addition vectors have been generated and evaluated by exvivo erythropoiesis models and mouse models for its therapeutical application in sickle cell disease and beta-thalassaemia In another strategy, an efficient lentiviral vector for the erythroid cell specific expression of BCL11A shRNA has been generated. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1802,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[25],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v16.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\r\n<title>Lentiviral Gene Therapy Approach for Haemoglobinopathies - CSCR NAHD<\/title>\r\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\r\n<link rel=\"canonical\" href=\"https:\/\/www.cscr.res.in\/nahd\/lentiviral-gene-therapy-approach-for-haemoglobinopathies\/\" \/>\r\n<meta property=\"og:locale\" content=\"en_US\" \/>\r\n<meta property=\"og:type\" content=\"article\" \/>\r\n<meta property=\"og:title\" content=\"Lentiviral Gene Therapy Approach for Haemoglobinopathies - CSCR NAHD\" \/>\r\n<meta property=\"og:description\" content=\"Lentiviral Gene Therapy Approach for Haemoglobinopathies Novel beta and gamma globin gene addition vectors have been generated and evaluated by exvivo erythropoiesis models and mouse models for its therapeutical application in sickle cell disease and beta-thalassaemia In another strategy, an efficient lentiviral vector for the erythroid cell specific expression of BCL11A shRNA has been generated. [&hellip;]\" \/>\r\n<meta property=\"og:url\" content=\"https:\/\/www.cscr.res.in\/nahd\/lentiviral-gene-therapy-approach-for-haemoglobinopathies\/\" \/>\r\n<meta property=\"og:site_name\" content=\"CSCR NAHD\" \/>\r\n<meta property=\"article:published_time\" content=\"2021-05-05T11:44:49+00:00\" \/>\r\n<meta property=\"article:modified_time\" content=\"2021-05-10T10:41:22+00:00\" \/>\r\n<meta property=\"og:image\" content=\"http:\/\/www.cscr.res.in\/nahd\/jb-content\/uploads\/2021\/03\/lentrival-post2.jpg\" \/>\r\n\t<meta property=\"og:image:width\" content=\"410\" \/>\r\n\t<meta property=\"og:image:height\" content=\"230\" \/>\r\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\r\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cscr.res.in\/nahd\/#website\",\"url\":\"https:\/\/www.cscr.res.in\/nahd\/\",\"name\":\"CSCR NAHD\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":\"https:\/\/www.cscr.res.in\/nahd\/?s={search_term_string}\",\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/www.cscr.res.in\/nahd\/lentiviral-gene-therapy-approach-for-haemoglobinopathies\/#primaryimage\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/www.cscr.res.in\/nahd\/jb-content\/uploads\/2021\/03\/lentrival-post2.jpg\",\"contentUrl\":\"https:\/\/www.cscr.res.in\/nahd\/jb-content\/uploads\/2021\/03\/lentrival-post2.jpg\",\"width\":410,\"height\":230},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cscr.res.in\/nahd\/lentiviral-gene-therapy-approach-for-haemoglobinopathies\/#webpage\",\"url\":\"https:\/\/www.cscr.res.in\/nahd\/lentiviral-gene-therapy-approach-for-haemoglobinopathies\/\",\"name\":\"Lentiviral Gene Therapy Approach for Haemoglobinopathies - CSCR NAHD\",\"isPartOf\":{\"@id\":\"https:\/\/www.cscr.res.in\/nahd\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cscr.res.in\/nahd\/lentiviral-gene-therapy-approach-for-haemoglobinopathies\/#primaryimage\"},\"datePublished\":\"2021-05-05T11:44:49+00:00\",\"dateModified\":\"2021-05-10T10:41:22+00:00\",\"author\":{\"@id\":\"https:\/\/www.cscr.res.in\/nahd\/#\/schema\/person\/901630f2506631b151a248df716d1cd0\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.cscr.res.in\/nahd\/lentiviral-gene-therapy-approach-for-haemoglobinopathies\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cscr.res.in\/nahd\/lentiviral-gene-therapy-approach-for-haemoglobinopathies\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cscr.res.in\/nahd\/lentiviral-gene-therapy-approach-for-haemoglobinopathies\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"item\":{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cscr.res.in\/nahd\/\",\"url\":\"https:\/\/www.cscr.res.in\/nahd\/\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"position\":2,\"item\":{\"@id\":\"https:\/\/www.cscr.res.in\/nahd\/lentiviral-gene-therapy-approach-for-haemoglobinopathies\/#webpage\"}}]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cscr.res.in\/nahd\/#\/schema\/person\/901630f2506631b151a248df716d1cd0\",\"name\":\"cscr-nahd\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/www.cscr.res.in\/nahd\/#personlogo\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2851170074b8dc7b944d37ba6e65f5de?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2851170074b8dc7b944d37ba6e65f5de?s=96&d=mm&r=g\",\"caption\":\"cscr-nahd\"},\"sameAs\":[\"http:\/\/www.cscr.res.in\/nahd\"],\"url\":\"https:\/\/www.cscr.res.in\/nahd\/author\/nahd_userlogin\/\"}]}<\/script>\r\n<!-- \/ Yoast SEO plugin. -->","_links":{"self":[{"href":"https:\/\/www.cscr.res.in\/nahd\/wp-json\/wp\/v2\/posts\/2652"}],"collection":[{"href":"https:\/\/www.cscr.res.in\/nahd\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cscr.res.in\/nahd\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cscr.res.in\/nahd\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cscr.res.in\/nahd\/wp-json\/wp\/v2\/comments?post=2652"}],"version-history":[{"count":9,"href":"https:\/\/www.cscr.res.in\/nahd\/wp-json\/wp\/v2\/posts\/2652\/revisions"}],"predecessor-version":[{"id":2738,"href":"https:\/\/www.cscr.res.in\/nahd\/wp-json\/wp\/v2\/posts\/2652\/revisions\/2738"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cscr.res.in\/nahd\/wp-json\/wp\/v2\/media\/1802"}],"wp:attachment":[{"href":"https:\/\/www.cscr.res.in\/nahd\/wp-json\/wp\/v2\/media?parent=2652"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cscr.res.in\/nahd\/wp-json\/wp\/v2\/categories?post=2652"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cscr.res.in\/nahd\/wp-json\/wp\/v2\/tags?post=2652"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}